NYSE - Nasdaq Real Time Price • USD
Eli Lilly and Company (LLY)
At close: May 17 at 4:00 PM EDT
After hours: May 17 at 7:58 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 20 | 21 |
| Avg. Estimate | 2.75 | 3.8 | 13.79 | 19.35 |
| Low Estimate | 2.28 | 3.6 | 13.2 | 16.3 |
| High Estimate | 3.25 | 4.17 | 14.28 | 21.27 |
| Year Ago EPS | 2.11 | 0.1 | 6.32 | 13.79 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 12 | 21 | 21 |
| Avg. Estimate | 9.99B | 11.34B | 43.11B | 53.22B |
| Low Estimate | 9.53B | 11.02B | 42.37B | 47.86B |
| High Estimate | 10.38B | 11.79B | 44.69B | 56.59B |
| Year Ago Sales | 8.31B | 9.5B | 34.12B | 43.11B |
| Sales Growth (year/est) | 20.20% | 19.30% | 26.30% | 23.50% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 1.98 | -0.13 | 2.22 | 2.46 |
| EPS Actual | 2.11 | 0.1 | 2.49 | 2.58 |
| Difference | 0.13 | 0.23 | 0.27 | 0.12 |
| Surprise % | 6.60% | 176.90% | 12.20% | 4.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.75 | 3.8 | 13.79 | 19.35 |
| 7 Days Ago | 2.75 | 3.8 | 13.8 | 19.48 |
| 30 Days Ago | 2.79 | 3.39 | 12.5 | 18.22 |
| 60 Days Ago | 2.76 | 3.36 | 12.51 | 18.21 |
| 90 Days Ago | 2.43 | 2.97 | 11.05 | 16.06 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 2 | 2 |
| Up Last 30 Days | 8 | 14 | 22 | 19 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LLY | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 30.30% | -- | -- | 8.00% |
| Next Qtr. | 3,700.00% | -- | -- | 12.40% |
| Current Year | 118.20% | -- | -- | 5.60% |
| Next Year | 40.30% | -- | -- | 13.00% |
| Next 5 Years (per annum) | 56.73% | -- | -- | 11.14% |
| Past 5 Years (per annum) | -3.09% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Argus Research: Buy to Buy | 5/14/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 5/1/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/1/2024 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 5/1/2024 |
| Maintains | Truist Securities: Buy to Buy | 5/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/30/2024 |
Related Tickers
ABBV AbbVie Inc.
166.42
+1.26%
AMGN Amgen Inc.
312.47
-0.71%
MRK Merck & Co., Inc.
131.19
+0.24%
PFE Pfizer Inc.
28.64
-0.97%
JNJ Johnson & Johnson
154.64
+0.23%
BMY Bristol-Myers Squibb Company
44.03
-0.18%
BIIB Biogen Inc.
230.57
+0.23%
GILD Gilead Sciences, Inc.
67.72
-0.21%
AZN AstraZeneca PLC
76.90
-0.18%
NVS Novartis AG
102.57
-0.12%